Global Cord Blood Corporation (CO) Misses Q3 EPS by 6c, Revenues Miss

Global Cord Blood Corporation (NYSE: CO) reported Q3 EPS of $0.07, $0.06 worse than the analyst estimate of $0.13. Revenue for the quarter came in at $37 million versus the consensus estimate of $39.36 million.

• Revenues increased by 3.7% year over year (\"YoY\") to RMB254.2 million ($37.0 million).
• New subscribers and accumulated subscriber base were 23,663 and 728,279[1], respectively.
• Gross profit increased by 3.9% YoY to RMB205.9 million ($30.0 million).
• Gross margin increased marginally from 80.9% in the prior year period to 81.0%.
• Operating income increased by 18.1% YoY to RMB92.6 million ($13.5 million).
• Operating income before depreciation and amortization and share-based compensation expenses[2] (\"non-GAAP operating income\") was down by 4.9% YoY to RMB105.3 million ($15.3 million), in light of higher sales and marketing expenses.
• Net income attributable to the Company\'s shareholders was RMB61.4 million ($8.9 million) compared to RMB69.9 million in the prior year period, after taking into account the unrealized holding loss of RMB28.4 million ($4.1 million) for equity securities, or more commonly known as mark-to-market loss, following the adoption of a new accounting standard[3].
• Net cash provided by operating activities for the third quarter of fiscal 2019 was RMB183.7 million ($26.7 million).

For earnings history and earnings-related data on Global Cord Blood Corporation (CO) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c
• HeartCore Enterprises, Inc. (HTCR) Misses Q2 EPS by 185c